

## **Anti-HGFR/c-Met Antibody (Emibetuzumab)**

## Introduction



Emibetuzumab (LY2875358) is a humanized bivalent MET antibody (IgG4 type). Emibetuzumab has high neutralization and internalization activity, and can effectively inhibit the activation of HGF-dependent and independent MET pathways and tumor growth. Emibetuzumab can be used in cancer research.

## Product parameters

Alternative Names	LY2875358
Target Accession	P08581
Target	HGFR / c-Met
CAS number	1365287-97-3
Molecular Weight	144.56 kDa
Host	СНО
Reactivity	Human APExBIO
Conjugation	Unconjugated Action Perfection, Explire the Outroom
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG4SP
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human c MET His at 2 ug/mL can bind Anti-HGFR/c-Met Antibody (Emibetuzumab EC50=0.004797 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration.  Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80℃
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## Note

1. This product is for scientific research use only.









